"We are clinical pharmacologists and drug developers with innate ability to aid in solving drug development challenges and developing straight forward strategies for successful therapies."
Dr. Sanela Bilic is a highly respected professional with proven leadership skills and nearly 20 years of broad experience within pharmaceutical drug development. She has extensive hands on and strategic experience with all phases of drug development globally. Sanela possesses broad knowledge of drug development principles and practice ranging from target identification, to early proof of concept, to tox interrogation, to IND, to early clinical development and to mature development of small and large molecules and cell therapies. She is especially focused on development of immuno-oncology therapeutics, cell therapies and ADCs. In addition, Sanela has extensive regulatory interaction experience with all major global health authorities.
After obtaining a Doctorate in Pharmacy and an MBA, Sanela completed a 2 year fellowship in Drug Development from SUNY at Buffalo and Novartis Pharmaceuticals in Oncology. She started her professional life in the Oncology clinical pharmacology department at Novartis. Following Sanela’ exponential professional as well as personal growth with Novartis, she joined D3 Medicine (now Certara) as a Senior Director, Clinical Pharmacology. During her years at Novartis and Certara (D3 Medicine), Sanela was an integral part of development team with extensive experience as the clinical pharmacology lead for global regulatory authority interactions. Sanela has worked as a clinical pharmacology leader between research and early development, early development and late development, and has lead due diligence efforts from clinical pharmacology perspective to aid in thorough assessment of business development opportunities. Sanela has led the clinical pharmacology strategic development of over 50 assets from preclinical development/research stage to end of phase 2 and beyond.